Skip to content

Prevention of Preterm Birth With a Pessary in Singleton Gestations

Prevention of Preterm Birth With a Pessary in Singleton Gestations

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02056652
Acronym
PoPPS
Enrollment
122
Registered
2014-02-06
Start date
2014-02-28
Completion date
2016-11-30
Last updated
2018-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Birth, Short Cervix

Keywords

Preterm birth, Preterm delivery, short cervix, pessary

Brief summary

Preterm birth (PTB) is associated with over one million infant deaths annually worldwide. The incidence of PTB in the United States is 11.5% with more than 500,000 deliveries occurring at less than 37 weeks gestation annually. The rate of PTB in the United States increased to 12.8% in 2006, and remains high compared to almost all other developed countries, despite the introduction of many public health and medical interventions designed to delay PTB. Weekly treatment with 17-alpha hydroxyprogesterone caproate beginning at 16-20 weeks gestation has been shown to significantly reduce the risk of PTB and is currently recommended for women who experienced spontaneous PTB in a prior pregnancy. However, a strategy for the prevention of spontaneous PTBs in which therapeutic intervention is restricted to women with a previous PTB is likely to have a small effect on the overall rate of prematurity since only about 10% of spontaneous PTBs arise in women with such a history. A major reduction in rates of mortality and morbidity in premature babies will only be achieved with increased precision in the identification of women at risk of spontaneous PTB and through the development of an effective prevention for this complication. Transvaginal ultrasound measurement of cervical length is a reliable screening test for prediction of PTB. Although treatment with vaginal progesterone is effective in decreasing PTB in women with a short cervix, over 30% of women still experience premature delivery and many women find daily administration of progesterone to be challenging. Preliminary studies have suggested that use of an intravaginal pessary may be effective in preventing PTB. If effective this approach would be particularly appealing because of the wide availability of pessaries, ease of use, and low cost. Unfortunately, existing studies are inadequate to confirm effectiveness; a well designed, properly powered, prospective randomized trial is warranted prior to widespread implementation in clinical practice. We propose such a trial to study the effectiveness of the pessary in decreasing the incidence of PTB in an inner city Philadelphia population.

Interventions

Sponsors

University of Pennsylvania
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* 18-50 years of age * Singleton pregnancy (limits the participants to female gender) * Short cervical length (less than or equal to 25 mm) on second trimester ultrasound at 18-23 6/7 weeks gestation

Exclusion criteria

* Multiple gestation * Prior spontaneous preterm birth 16-36 6/7 weeks * Ruptured membranes * Lethal fetal structural anomaly * Fetal chromosomal abnormality * Cerclage in place (or planned placement) * Vaginal bleeding * Suspicion of chorioamnionitis * Ballooning of membranes outside the cervix into the vagina or CL = 0 mm on transvaginal ultrasound * Painful regular uterine contractions * Placenta previa

Design outcomes

Primary

MeasureTime frameDescription
Number of Subjects Experiencing Preterm BirthBefore 37 weeks gestation (20 0/7 - 36 6/7 weeks)Birth before 37 weeks gestation was captured.

Secondary

MeasureTime frameDescription
Average Birth Weight of Babies Born on TrialTime of deliveryThe birth weights of babies born in the pessary group was compared to those born in the no pessary group
Number of Participants That Experienced Spontaneous Preterm Births on TrialBefore 37 weeks gestationThe number of spontaneous births that occurred in participants on trial before 37 weeks was captured.
Number of Participants Experiencing Spontaneous Rupture of MembranesLess than 34 weeks gestationRupture of membranes before 34 weeks gestation was captured in each group.
Number of Subjects Experiencing Neonatal DeathBetween birth and 28 days of ageNumber of participants who experienced neonatal deaths from birth to day 28 was captured for each group.
Number of Subjects Experiencing ChorioamnionitisTime of deliveryThe AE of Chorioamnionitis was captured for each group.

Countries

United States

Participant flow

Participants by arm

ArmCount
Pessary
Use of the Bioteque cup pessary. Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated) Bioteque cup pessary
61
No Pessary
No pessary will be used. Subjects will receive standard obstetrical management
61
Total122

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up03
Overall StudyWithdrawal by Subject10

Baseline characteristics

CharacteristicPessaryNo PessaryTotal
Age, Customized
Maternal Age
27.7 years29.5 years28.6 years
Region of Enrollment
United States
61 Participants61 Participants122 Participants
Sex: Female, Male
Female
61 Participants61 Participants122 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 610 / 61
other
Total, other adverse events
3 / 616 / 61
serious
Total, serious adverse events
0 / 610 / 61

Outcome results

Primary

Number of Subjects Experiencing Preterm Birth

Birth before 37 weeks gestation was captured.

Time frame: Before 37 weeks gestation (20 0/7 - 36 6/7 weeks)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
PessaryNumber of Subjects Experiencing Preterm Birth26 Participants
No PessaryNumber of Subjects Experiencing Preterm Birth23 Participants
Secondary

Average Birth Weight of Babies Born on Trial

The birth weights of babies born in the pessary group was compared to those born in the no pessary group

Time frame: Time of delivery

ArmMeasureValue (MEAN)
PessaryAverage Birth Weight of Babies Born on Trial2788 grams
No PessaryAverage Birth Weight of Babies Born on Trial2843 grams
Secondary

Number of Participants Experiencing Spontaneous Rupture of Membranes

Rupture of membranes before 34 weeks gestation was captured in each group.

Time frame: Less than 34 weeks gestation

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
PessaryNumber of Participants Experiencing Spontaneous Rupture of Membranes18 Participants
No PessaryNumber of Participants Experiencing Spontaneous Rupture of Membranes10 Participants
Secondary

Number of Participants That Experienced Spontaneous Preterm Births on Trial

The number of spontaneous births that occurred in participants on trial before 37 weeks was captured.

Time frame: Before 37 weeks gestation

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
PessaryNumber of Participants That Experienced Spontaneous Preterm Births on Trial23 Participants
No PessaryNumber of Participants That Experienced Spontaneous Preterm Births on Trial19 Participants
Secondary

Number of Subjects Experiencing Chorioamnionitis

The AE of Chorioamnionitis was captured for each group.

Time frame: Time of delivery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
PessaryNumber of Subjects Experiencing Chorioamnionitis7 Participants
No PessaryNumber of Subjects Experiencing Chorioamnionitis4 Participants
Secondary

Number of Subjects Experiencing Neonatal Death

Number of participants who experienced neonatal deaths from birth to day 28 was captured for each group.

Time frame: Between birth and 28 days of age

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
PessaryNumber of Subjects Experiencing Neonatal Death3 Participants
No PessaryNumber of Subjects Experiencing Neonatal Death6 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026